---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025324"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-05-27T11:05:55+00:00"
generated_at: "2026-05-27T11:11:51.414313+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tonix publishes Phase 1 data for TNX-1500; shows TDAR blockade, favorable safety

## Summary
- TNX-1500 Phase 1 data in Journal of Clinical Immunology; blocked primary TDAR at all doses (3,10,30 mg/kg).
- Secondary TDAR blocked at 10 and 30 mg/kg; peak secondary reduced ~70% vs placebo at 3 mg/kg.
- No serious adverse events; mild aphthous ulcers in 3 participants; half-life supports monthly IV dosing.
- Phase 2 investigator-initiated kidney transplant study at MGH expected to start 2H 2026 pending FDA IND clearance.

## SEC filing metadata
- accession: 0001493152-26-025324
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-05-27T11:05:55+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000149315226025324/0001493152-26-025324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000149315226025324/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025324
- JSON: https://secwatch.observer/filing/0001493152-26-025324.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.